(CercleFinance.com) – DMS Group reported on Friday evening its results for the 2021 financial year, marked by “dynamic” growth in activity and a “record” operating margin.
The medical imaging group announces that it achieved consolidated revenue of 37 million euros last year, representing organic growth of 16% compared to 2020.
DMS indicates that it generated a gross operating surplus (EBITDA) of 1.9 million euros, compared to a break-even result in 2020, representing a record EBITDA margin of 5.1%.
The EBITDA of the DMS Imaging subsidiary (formerly Asit biotech) alone stood at 2.5 million euros in 2021, almost double compared to the 2020 financial year, which corresponds to a margin of 6.8%.
In its press release, the group says it has started the 2022 financial year well, with a turnover of 8.9 million euros in the 1st quarter, a level of activity comparable to that achieved in the 4th quarter of 2021.
This turnover is also stable compared to that of the 1st quarter of 2021, which had been marked by a high level of billings in the radiology activity due to the delivery of a major contract obtained from the World Bank.
After the publication of these figures, the DMS title posted an increase of more than 5% on Monday morning on the Paris Stock Exchange, giving a market capitalization of 18 million euros. Since the beginning of the year, the share price is still down by more than 10%.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
Are you following this action?
Receive all the information about DIAGNOSTIC MEDICAL in real time: